WO2003004622A3 - Human secreted proteins - Google Patents

Human secreted proteins Download PDF

Info

Publication number
WO2003004622A3
WO2003004622A3 PCT/US2002/008124 US0208124W WO03004622A3 WO 2003004622 A3 WO2003004622 A3 WO 2003004622A3 US 0208124 W US0208124 W US 0208124W WO 03004622 A3 WO03004622 A3 WO 03004622A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Application number
PCT/US2002/008124
Other languages
French (fr)
Other versions
WO2003004622A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to CA002441416A priority Critical patent/CA2441416A1/en
Priority to AU2002354719A priority patent/AU2002354719A1/en
Priority to EP02782476A priority patent/EP1414845A4/en
Publication of WO2003004622A2 publication Critical patent/WO2003004622A2/en
Priority to US10/664,357 priority patent/US20070055056A1/en
Publication of WO2003004622A3 publication Critical patent/WO2003004622A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diabetes mellitus and/or conditions related to diabetes. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of, polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the jpolypeptides of the present invention.
PCT/US2002/008124 1997-03-07 2002-03-19 Human secreted proteins WO2003004622A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002441416A CA2441416A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002354719A AU2002354719A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02782476A EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
US10/664,357 US20070055056A1 (en) 1997-03-07 2003-09-20 251 human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/981,876 Continuation-In-Part US7053190B2 (en) 1997-03-07 2001-10-19 Secreted protein HRGDF73
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/664,357 Continuation-In-Part US20070055056A1 (en) 1997-03-07 2003-09-20 251 human secreted proteins

Publications (2)

Publication Number Publication Date
WO2003004622A2 WO2003004622A2 (en) 2003-01-16
WO2003004622A3 true WO2003004622A3 (en) 2004-02-19

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications Before (6)

Application Number Title Priority Date Filing Date
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1379264A4 (en)
AU (6) AU2002324424A1 (en)
CA (7) CA2441702A1 (en)
WO (7) WO2002102994A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (en) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
BR0007556A (en) 1999-01-15 2001-10-23 Biogen Inc Tweak and tweak receptor antagonists and their use to treat immune disorders
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
CA2443123A1 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
CA2463596A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
CN103536916B (en) 2002-04-09 2016-08-17 比奥根Ma公司 For the method treating TWEAK associated conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE602004025157D1 (en) 2003-09-23 2010-03-04 Univ North Carolina Cells that co-express vitamin K reductase and vitamin K-dependent protein and their application to improve the productivity of this vitamin K-dependent protein
ES2344413T3 (en) * 2003-10-14 2010-08-26 Baxter International Inc. VKORC1 POLYPEPTIDE FOR RECYCLING VITAMIN K-EPOXIDE, A THERAPEUTIC TARGET OF CUMARINE AND ITS DERIVATIVES.
EP1714154A2 (en) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2578775C (en) 2004-09-01 2016-05-03 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
EP1799850A4 (en) * 2004-09-07 2009-02-11 Telethon Inst For Child Health Method of diagnosing and/or predicting the development of an allergic disorder
CA2579349A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Agents for treatment or prevention of an allergic disorder
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc Treating neurological disorders
EP2295547B1 (en) 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2470843B (en) * 2005-09-01 2011-04-13 Florey Howard Inst Models and methods for the assessment of potential therapeutic agents for the modulation of NDFIP1-NEDD4 interactions
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications
JP5588175B2 (en) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション PCSK9 antagonist
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7456605B2 (en) 2016-12-23 2024-03-27 プレジデント アンド フェローズ オブ ハーバード カレッジ PCSK9 gene editing
JP7247101B2 (en) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to STEAP-1
US10450119B2 (en) 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
US11192139B2 (en) 2017-06-22 2021-12-07 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
AU2021253959A1 (en) 2020-04-09 2022-11-17 Verve Therapeutics, Inc. Base editing of PCSK9 and methods of using same for treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013773A (en) * 1996-02-02 2000-01-11 Mitsui Chemicals, Inc. Pharmaceutical preparation containing human growth hormone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
CA2333917A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013773A (en) * 1996-02-02 2000-01-11 Mitsui Chemicals, Inc. Pharmaceutical preparation containing human growth hormone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1414845A4 *

Also Published As

Publication number Publication date
CA2441755A1 (en) 2003-05-08
EP1423134A2 (en) 2004-06-02
CA2441397A1 (en) 2002-10-03
WO2002102994A3 (en) 2003-07-24
WO2002095010A2 (en) 2002-11-28
WO2003004622A2 (en) 2003-01-16
WO2002076488A1 (en) 2002-10-03
WO2002090526A3 (en) 2003-10-30
WO2002102994A2 (en) 2002-12-27
EP1390390A2 (en) 2004-02-25
EP1404702A2 (en) 2004-04-07
AU2002354719A1 (en) 2003-01-21
CA2441832A1 (en) 2002-12-27
AU2002332391A1 (en) 2003-01-02
CA2441702A1 (en) 2002-12-27
WO2002102993A2 (en) 2002-12-27
AU2002363296A1 (en) 2003-05-12
WO2003038063A2 (en) 2003-05-08
WO2002102993A3 (en) 2004-03-25
WO2003038063A3 (en) 2003-12-11
EP1379264A1 (en) 2004-01-14
EP1404702A4 (en) 2009-07-08
EP1381622A2 (en) 2004-01-21
CA2441840A1 (en) 2002-11-28
EP1414845A4 (en) 2009-07-08
AU2002326293A1 (en) 2003-01-02
EP1414845A2 (en) 2004-05-06
EP1379264A4 (en) 2009-07-08
WO2002090526A2 (en) 2002-11-14
EP1390390A4 (en) 2009-07-08
EP1379132A4 (en) 2009-07-01
CA2441417A1 (en) 2002-11-14
AU2002324424A1 (en) 2002-12-03
CA2441416A1 (en) 2003-01-16
AU2002320013A1 (en) 2002-11-18
EP1379132A2 (en) 2004-01-14
WO2002095010A3 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2003004622A3 (en) Human secreted proteins
WO2003000865A3 (en) Human secreted proteins
WO2001055318A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2001055326A8 (en) Nucleic acids, proteins, and antibodies
WO2004042000A3 (en) 157 human secreted proteins
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10664357

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2441416

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002782476

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002782476

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10664357

Country of ref document: US